报道:Citius Pharmaceuticals 2024财年每股收益为$(5.97),同比下降$(5.57);现金为330万美元

财报速递
30 Dec 2024
截至2024年9月30日,Citius Pharmaceuticals的净亏损为3940万美元,即每股亏损($5.97),相比2023年9月30日的净亏损为3250万美元,即每股亏损($5.57),已调整为反向股票分割。净亏损增加反映了530万美元的运营费用增加,被160万美元的其他收入减少所抵消。运营费用增加是由于股票补偿和一般管理费用增加,但被减少的研发费用所抵消。 截至2024年9月30日,公司拥有330万美元的现金和现金等价物。

以上内容来自Benzinga Earnings专栏,原文如下:

Net loss was $39.4 million, or ($5.97) per share for the year ended September 30, 2024, compared to a net loss of $32.5 million, or ($5.57) per share for the year ended September 30, 2023, as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense.

As of September 30, 2024, the Company had $3.3 million in cash and cash equivalents.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10